AOD-9604 vs Tesamorelin
Head-to-head comparison of AOD-9604 and Tesamorelin for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Aod 9604 | Tesamorelin |
|---|---|---|
| Category | Metabolic / Fat Loss | Growth Hormone Secretagogue |
| Mechanism | AOD-9604 (C78H123N23O23S2) works through a dual-action mechanism: it accelerates breakdown of stored fat (lipolysis) via cAMP signaling and enzymatic activation (stimulating hormone-sensitive lipase), while simultaneously blocking formation of new fat (lipogenesis). | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. |
| Evidence Rating | C — Phase I–II Clinical Trials | A — FDA Approved |
| Clinical Status | Clinical development discontinued after Phase 2; GRAS status for food use | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy |
| Safety Profile | In extensive clinical trials, side effect profile was virtually indistinguishable from placebo; Mild headaches or flushing reported in small percentage of users | Headache, nausea, and flu-like symptoms reported; May increase blood glucose -- monitoring recommended in diabetics |
| Molecular Weight | ~1815.1 g/mol | ~5135.9 g/mol |
| Half-Life | ~30 minutes | ~26–38 minutes |
Overview
AOD-9604 and Tesamorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
AOD-9604 — Mechanism & Evidence
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191 plus an N-terminal tyrosine, Tyr-hGH(177-191)) developed at Monash University, Australia. It retains the lipolytic (fat-burning) properties of HGH while discarding the growth-promoting and diabetogenic effects. It underwent six randomized, double-blind, placebo-controlled human clinical trials for obesity in the early 2000s, showing modest but consistent fat loss (~5% body weight) with a side effect profile indistinguishable from placebo. The FDA granted it GRAS status for food use in 2014, though clinical development for obesity was discontinued.
Key claims: Promotes fat loss without growth effects; Does not affect blood sugar or IGF-1; May help with cartilage repair.
Tesamorelin 10mg
10mg
Tesamorelin — Mechanism & Evidence
Tesamorelin (tesamorelin acetate) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) and the only FDA-approved medication for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, marketed as Egrifta. It stimulates endogenous GH and IGF-1 production. Egrifta WR, a new weekly-reconstitution formulation, was FDA-approved in March 2025. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.
Shared Research Applications
These peptides target different research areas. AOD-9604 focuses on Fat Loss, while Tesamorelin targets Body Composition.
Safety Considerations
AOD-9604: In extensive clinical trials, side effect profile was virtually indistinguishable from placebo Mild headaches or flushing reported in small percentage of users No growth effects: does not increase IGF-1, so zero risk of abnormal bone growth or organ enlargement
Tesamorelin: Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics FDA pregnancy category X -- tesamorelin can harm an unborn baby or cause birth defects
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
Tesamorelin Research Interest Grows Among Synthetic GHRPs
Synthetic growth hormone-releasing peptides (GHRPs) are drawing increasing attention in scientific research, with tesamorelin emerging as a focal point. The compound, a synthetic analog of growth hormone-releasing hormone, is being studied for its potential to modulate growth hormone levels. This article examines the rising research interest in tesamorelin and its place within the broader class of synthetic GHRPs.